Coegin Pharma AB ("Coegin") is delighted to announce that Professor Desmond J. Tobin, a globally recognized leader in skin and hair pigmentation science and hair-follicle biology, has been appointed as a Scientific Advisor. Prof. Tobin is the co-inventor behind Coegin's skin pigmentation peptide, NPP-4. His expertise directly aligns with Coegin's focus on skin pigmentation and hair growth.                                                                                                               

Prof. Tobin brings an extraordinary track record spanning decades of pioneering research in melanocyte and hair-follicle biology. He has authored almost 200 peer-reviewed publications, including landmark works such as "The cell biology of human hair follicle pigmentation" and "Melanin pigmentation in mammalian skin and its hormonal regulation".

His research has advanced the understanding of multiple fundamental aspects of pigmentation and hair biology, including the close link between pigmentation and hair growth. 

Importantly, while at the University of Bradford, Prof. Tobin and his team uncovered a novel mechanism for topically modulating skin pigmentation: a peptide-based mimic of a natural signaling protein that influences melanocyte activity. With this depth of mechanistic insight into both pigmentation and hair-biology, Prof. Tobin will advise Coegin on the company's skin-pigmentation peptide NPP-4, the Follicopeptide hair-growth assets, and broader translational opportunities relating to follicular pigmentation.

In addition, Coegin is pleased to confirm that Professors Anna Hultgårdh Nilsson and Jan Nilsson of Lund University - both inventors behind Coegin's proprietary peptide platform (including the active ingredient known commercially as Follicopeptide) - also serve as strategic advisors to Coegin's peptide innovation programmes.

Professor Anna Hultgårdh Nilsson (Lund University) is a recognized expert in peptide biology and tissue repair, with a strong track record of innovation in hair and peptide technology. Her research has documented novel peptides derived from the natural glycoprotein osteopontin that stimulate hair-follicle initiation and growth. As one of the inventors of Follicopeptide, her strategic insight into peptide design and translation is central to Coegin's ambitions in hair growth and cosmetic dermatology.

Professor Jan Nilsson (Lund University) is a world-renowned clinical researcher in metabolic disease, tissue repair, and peptide innovation. He is listed among the research leaders behind the development of Follicopeptide for hair growth and the broader FOL-peptide family. His strategic experience in translation to commercial products adds substantial value to Coegin's advisory team.

"We are very pleased to welcome Professor Tobin as Scientific Advisor to Coegin. His internationally recognized expertise in pigmentation and hair-follicle biology brings highly valuable scientific depth to our development programmes, including NPP-4. Together with Professors Hultgårdh Nilsson and Nilsson, who provide long-standing continuity and deep insight into our proprietary peptide platform, we have an exceptional advisory foundation that strongly supports our ambition to translate cutting-edge peptide science into differentiated products with clear market relevance," says Jens Eriksson, CEO of Coegin Pharma.

For further information, please contact:
Jens Eriksson, CEO, Coegin Pharma AB
Email: je@coeginpharma.com

About Coegin Pharma
Coegin Pharma is a Swedish biotech company with cutting-edge innovations for hair and skin. The company is currently commercializing its patented hair growth innovation Follicopeptide® on a global scale. In development is NPP-4, a next-generation peptide that represents a novel approach to regulating skin pigmentation through advanced biotechnology.

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden. 

More information - including subscription to company updates and links to social media - is available at coeginpharma.com

Attached files